NASDAQ:WGS GeneDx (WGS) Stock Price, News & Analysis $62.37 -1.99 (-3.09%) Closing price 11/6/2026 04:00 PM EasternExtended Trading$63.09 +0.72 (+1.15%) As of 11/6/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About GeneDx Stock (NASDAQ:WGS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GeneDx alerts:Sign Up Key Stats Today's Range$58.75▼$66.3550-Day Range$56.15▼$104.9552-Week Range$32.21▼$170.87Volume1.20 million shsAverage Volume827,828 shsMarket Capitalization$1.86 billionP/E RatioN/ADividend YieldN/APrice Target$90.86Consensus RatingModerate Buy Company Overview GeneDx Holdings Corp., doing business as GeneDx, is a genomic diagnostics company that provides genetic testing and interpretation services for patients with suspected rare and inherited conditions. The company combines sequencing technologies with clinical expertise and data analysis to help healthcare professionals identify genetic causes of disease and support diagnosis, treatment planning and patient management. GeneDx’s offerings include whole exome and whole genome sequencing, as well as targeted testing for specific genetic disorders and hereditary cancer conditions. Its services are used by physicians, hospitals, health systems and other healthcare organizations, and the company also provides educational and interpretive resources intended to help clinicians understand genetic test results. Founded in 2000, GeneDx was initially established to focus on genetic testing for rare diseases. The business was acquired by BioReference Laboratories in 2014 and later became part of Sema4, which acquired GeneDx from OPKO Health in 2022. Sema4 subsequently changed its corporate name to GeneDx Holdings Corp. and trades on the Nasdaq under the symbol WGS. GeneDx primarily serves the U.S. healthcare market through healthcare providers and institutions, while its genomic testing and data capabilities support research and biopharmaceutical activities. The company is led by Chief Executive Officer Katherine Stueland.AI Generated. May Contain Errors. Read More GeneDx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreWGS MarketRank™: 2.473118279565 of 5 starsGeneDx scored higher than 49% of companies evaluated by MarketBeat, and ranked 507th out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingGeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialGeneDx has a consensus price target of $90.86, representing about 45.7% upside from its current price of $62.37.Amount of Analyst CoverageGeneDx has only been the subject of 3 research reports in the past 90 days.Read more about GeneDx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for GeneDx are expected to grow in the coming year, from ($0.41) to $1.15 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GeneDx is -17.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GeneDx is -17.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeneDx has a P/B Ratio of 5.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GeneDx's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted26.98% of the float of GeneDx has been sold short.Short Interest Ratio / Days to CoverGeneDx has a short interest ratio ("days to cover") of 8.73.Change versus previous monthShort interest in GeneDx has recently increased by 7.02%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeneDx does not currently pay a dividend.Dividend GrowthGeneDx does not have a long track record of dividend growth. News and Social Media1.5 / 5News Sentiment0.40 News SentimentGeneDx has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for GeneDx this week, compared to 8 articles on an average week.Search InterestOnly 1 people have searched for WGS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, GeneDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,808,056.00 in company stock.Percentage Held by Insiders25.17% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GeneDx's insider trading history. Receive WGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeneDx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. WGS Stock News HeadlinesGeneDx (WGS) Projected to Release Earnings on Monday2 hours ago | americanbankingnews.comEarnings to Watch: GeneDx Holdings Corp (WGS) Q3 2026 -- GF Value Sees 44.00% UpsideNovember 6 at 8:30 AM | finance.yahoo.comWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected. | Porter & Company (Ad)GeneDx Holdings Corp. (WGS) - What Are Brokerages Thinking About This Stock?November 5 at 2:29 AM | americanbankingnews.comContrasting GeneDx (NASDAQ:WGS) & Getinge (OTCMKTS:GNGBY)November 4, 2026 | americanbankingnews.comDid GeneDx Holdings Corp. Insiders Breach their Fiduciary Duties to Shareholders?October 27, 2026 | prnewswire.comGeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026October 23, 2026 | businesswire.comGeneDx to Add Long-Read Whole Genome Sequencing to Testing PortfolioOctober 20, 2026 | marketscreener.comMSee More Headlines WGS Stock Analysis - Frequently Asked Questions How have WGS shares performed this year? GeneDx's stock was trading at $130.06 on January 1st, 2026. Since then, WGS shares have decreased by 52.0% and is now trading at $62.37. How were GeneDx's earnings last quarter? GeneDx Holdings Corp. (NASDAQ:WGS) posted its earnings results on Monday, August, 3rd. The company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.20. The company had revenue of $114.44 million for the quarter, compared to analysts' expectations of $111.01 million. GeneDx had a positive trailing twelve-month return on equity of 4.12% and a negative net margin of 23.41%. Read the conference call transcript. When did GeneDx's stock split? GeneDx's stock reverse split on Thursday, May 4th 2023.The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are GeneDx's major shareholders? Top institutional shareholders of GeneDx include William Blair Investment Management LLC (5.23%), Sumitomo Mitsui Trust Group Inc. (2.22%), Assenagon Asset Management S.A. (2.12%) and Gagnon Securities LLC (1.73%). Insiders that own company stock include Keith A Meister, Casdin Capital, Llc, School Of Medicine At Mo Icahn, Opko Health, Inc, Katherine Stueland, Kevin Feeley, Kareem Saad, Richard C Pfenniger Jr, Richard C Pfenniger Jr, Joshua Ruch, Jason Ryan and Bryan Dechairo. View institutional ownership trends. How do I buy shares of GeneDx? Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GeneDx own? Based on aggregate information from My MarketBeat watchlists, some other companies that GeneDx investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), CrowdStrike (CRWD), Advanced Micro Devices (AMD), Taiwan Semiconductor Manufacturing (TSM), Tesla (TSLA) and Alibaba Group (BABA). Company Calendar Last Earnings8/03/2026Today11/07/2026Next Earnings (Confirmed)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 13 days, WGS's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNASDAQ:WGS CIK1818331 Webwww.genedx.com Phone800-298-6470FaxN/AEmployees1,300Year Founded2000Price Target and Rating Average Price Target for GeneDx$90.86 High Price Target$150.00 Low Price Target$63.00 Potential Upside/Downside+45.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($3.64) Trailing P/E RatioN/A Forward P/E Ratio54.23 P/E GrowthN/ANet Income-$21.02 million Net Margins-23.41% Pretax Margin-23.39% Return on Equity4.12% Return on Assets2.26% Debt Debt-to-Equity Ratio0.40 Current Ratio3.30 Quick Ratio3.06 Sales & Book Value Annual Sales$427.54 million Price / Sales4.35 Cash Flow$2.29 per share Price / Cash Flow27.21 Book Value$10.54 per share Price / Book5.92Miscellaneous Outstanding Shares29,820,000Free Float22,317,000Market Cap$1.86 billion OptionableOptionable Beta2.00 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:WGS) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredThe IRS loophole Trump fought to preserve for retirees401(k) balances have reached record highs on a rising stock market and strong job growth. But traditional acco...American Hartford Gold | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredYour first step can stay on paperIncome Blueprint, created by Matt, helps traders find and evaluate options opportunities. In his walkthrough, ...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
